<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">956</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2024-19-3-233-242</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SUPPORTIVE THERAPY ASPECTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Nutritional deficiency in patients with newly diagnosed diffuse large B-cell lymphoma Prevalence and approaches to correction</article-title><trans-title-group xml:lang="ru"><trans-title>Нутритивная недостаточность у пациентов с впервые диагностированной диффузной В-крупноклеточной лимфомой. Распространенность и подходы к коррекции</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0197-7721</contrib-id><name-alternatives><name xml:lang="en"><surname>Obukhova</surname><given-names>O. A.</given-names></name><name xml:lang="ru"><surname>Обухова</surname><given-names>О. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Ol’ga A. Obuhova </bold></p><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><bold>Ольга Аркадьевна Обухова </bold></p><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><email>obukhova0404@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8463-2600</contrib-id><name-alternatives><name xml:lang="en"><surname>Kurmukov</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Курмуков</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4951-3053</contrib-id><name-alternatives><name xml:lang="en"><surname>Semenova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Семенова</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5881-1795</contrib-id><name-alternatives><name xml:lang="en"><surname>Lebedeva</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Лебедева</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7321-4323</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanova</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Иванова</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>2 Salyama Adilya St., Moscow 123423</italic></p></bio><bio xml:lang="ru"><p><italic>123423 Москва, ул. Саляма Адиля, 2</italic></p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2902-077X</contrib-id><name-alternatives><name xml:lang="en"><surname>Shagina</surname><given-names>N. Yu.</given-names></name><name xml:lang="ru"><surname>Шагина</surname><given-names>Н. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Build. 2, 8 Trubetskaya St., Moscow 119991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2</italic></p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Center of Coloproctology named after A.N. Ryzhikh, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр колопроктологии им. А.Н. Рыжих» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-09-03" publication-format="electronic"><day>03</day><month>09</month><year>2024</year></pub-date><volume>19</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>233</fpage><lpage>242</lpage><history><date date-type="received" iso-8601-date="2024-09-03"><day>03</day><month>09</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-09-03"><day>03</day><month>09</month><year>2024</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/956">https://oncohematology.abvpress.ru/ongm/article/view/956</self-uri><abstract xml:lang="en"><p><bold>Background.</bold><bold> </bold>Assessing nutritional status at the start of treatment for patients with diffuse large B-cell lymphoma allows us to plan adequate accompanying treatment for patients in whom early nutritional support can improve the results of antitumor treatment.</p><p><bold>Aim. </bold>To assess the prevalence of nutritional deficiency, features of usual diet energy and protein composition in patients with diffuse large B-cell lymphoma who are starting antitumor treatment.</p><p><bold>Materials and methods. </bold>The study included 96 adult patients (m = 61), average age 38.9 ± 16.8 years, with newly diagnosed diffuse large B-cell lymphoma of various localization and prevalence. Additional laboratory screening (total protein, albumin, C-reactive protein (CRP), total cholesterol, triglycerides, daily urea excretion), anthropometric measurements (height, body weight (BW), weight loss over 6 months, body mass index), questionnaire (considering the intake of nutrients during the previous 3 days, calculating the intake of protein and energy, nitrogen balance) were performed in all patients before the first course of antitumor treatment. GLIM (Global Leadership Initiative on Malnutrition) criteria were used to diagnose protein-energy malnutrition (PEM).</p><p><bold>Results. </bold>In studied patients, energy intake was 27.92 ± 6.47 kcal/kg BW per day, protein 0.91 ± 0.18 g/kg BW per day, and nitrogen balance was –3.57 ± 2.94 g/day. Moderate PEM was diagnosed in 37 (38.5 %) patients. Differences in some laboratory parameters were revealed in patients with PEM and without nutritional disorders: CRP level (20.38 ± 14.69 mg/L <italic>versus </italic>12.52 ± 5.66 mg/L; <italic>p </italic>= 0.0004), glucose (5.07 ± 1.09 mmol/L <italic>versus </italic>4.57 ± 0.62 mmol/L; <italic>p</italic><italic> </italic>= 0.005), total cholesterol (4.35 ± 1.27 mmol/L <italic>versus</italic><italic> </italic>5.36 ± 1.45 mmol/L), triglycerides (1.22 ± 0.51 mmol/L <italic>versus </italic>2.02 ± 0.78 mmol/L; <italic>p</italic><italic> </italic>= 0.001).</p><p><bold>Conclusion. </bold>Moderate PEM is detected in more than a third of patients with diffuse large B-cell lymphoma who begin antitumor treatment. The leading symptom in this case is unintentional weight loss over the past 6 months. An increased CRP level, moderate hyperglycemia, and lower concentrations of total cholesterol and blood triglycerides also characterize PEM in this cohort of patients. With sufficient energy supply, the amount of protein in the natural diet of patients with PEM turned out to be low, and the nitrogen balance was negative, which in the future can lead to the development of sarcopenia and requires nutritional support.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Оценка нутритивного статуса к моменту начала специфической терапии у пациентов, страдающих диффузной В-крупноклеточнной лимфомой, позволяет планировать адекватное сопроводительное лечение с целью улучшения непосредственных и отдаленных результатов противоопухолевой терапии.</p><p><bold>Цель исследования </bold>– оценить распространенность нутритивной недостаточности, изучить особенности энергетического и белкового состава рациона питания больных, страдающих диффузной В-крупноклеточной лимфомой, до начала противоопухолевой терапии.</p><p><bold>Материалы и методы. </bold>В исследование включены 96 пациентов (61 мужчина) с впервые диагностированной диффузной В-крупноклеточной лимфомой различной локализации и распространенности. Всем пациентам до начала противоопухолевой терапии дополнительно проведены лабораторный скрининг (определение уровня общего белка, альбумина, С-реактивного белка (СРБ), общего холестерина, триглицеридов, суточной экскреции мочевины), антропометрические измерения (рост, масса тела (МТ), снижение МТ за 6 мес, индекс массы тела), анкетирование (с учетом поступления нутриентов в течение 3 предыдущих суток, расчетом поступления белка и энергии); рассчитан баланс азота. Для диагностики белково-энергетической недостаточности (БЭН) применены критерии GLIM (Global Leadership Initiative on Malnutrition, Глобальный консенсус по проблемам неполноценного питания).</p><p><bold>Результаты.</bold><bold> </bold>У пациентов исследованной когорты поступление энергии составило 27,92 ± 6,47 ккал/кг МТ в сутки, белка – 0,91 ± 0,18 г/кг МТ в сутки, баланс азота был –3,57 ± 2,94 г/сут. БЭН средней степени тяжести диагностирована у 37 (38,5 %) больных. Выявлены различия некоторых лабораторных показателей у пациентов с БЭН и без нарушений питания: концентрации СРБ (20,38 ± 14,69 мг/л против 12,52 ± 5,66 мг/л; <italic>р </italic>= 0,0004), уровня глюкозы (5,07 ± 1,09 ммоль/л против 4,57 ± 0,62 ммоль/л; <italic>р</italic><italic> </italic>= 0,005), общего холестерина (4,35 ± 1,27 ммоль/л против 5,36 ± 1,45 ммоль/л; <italic>р </italic>= 0,0008), триглицеридов (1,22 ± 0,51 ммоль/л против 2,02 ± 0,78 ммоль/л; <italic>р </italic>= 0,001).</p><p><bold>Заключение. </bold>БЭН средней степени тяжести обнаружена более чем у трети пациентов с диффузной В-крупноклеточной лимфомой, начинающих противоопухолевое лечение. Ведущим симптомом при этом является непреднамеренное снижение МТ за последние полгода. Для БЭН в этой когорте пациентов характерны повышенный уровень СРБ, умеренная гипергликемия, более низкая концентрация общего холестерина и триглицеридов крови. При достаточной обеспеченности энергией, количество белка в рационе естественного питания пациентов с БЭН оказалось невысоким, а баланс азота – отрицательным, что в перспективе может привести к развитию саркопении и требует проведения нутритивной поддержки.</p></trans-abstract><kwd-group xml:lang="en"><kwd>diffuse large B-cell lymphoma</kwd><kwd>malnutrition</kwd><kwd>nutritional support</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>диффузная В-крупноклеточная лимфома</kwd><kwd>белково-энергетическая недостаточность</kwd><kwd>нутритивная поддержка</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The research and analytical work and publication preparation were carried out with the support of Fresenius Kabi Company</funding-statement><funding-statement xml:lang="ru">Поисково-аналитическая работа и подготовка публикации проведены при поддержке компании «Фрезениус Каби»</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">National Cancer Institute. Cancer Stat Facts: NHL – diffuse large B-cell lymphoma (DLBCL). 2020. Available at: https://seer.cancer.gov/statfacts/html/dlbcl.htm l</mixed-citation><mixed-citation xml:lang="ru">National Cancer Institute. Cancer Stat Facts: NHL – diffuse large B-cell lymphoma (DLBCL). 2020. Available at: https://seer.cancer.gov/statfacts/html/dlbcl.html</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Ivanova A.S., Obukhova O.A., Kurmukov I.A., Volf L.Ya. Review of ESPEN-2021 practice guidelines for cancer patients. Part 1. Klinicheskoe pitanie i metabolizm = Clinical Nutrition and Metabolism 2022;3(3):140–52. (In Russ.). DOI: https://doi.org/10.17816/clinutr111900</mixed-citation><mixed-citation xml:lang="ru">Иванова А.С., Обухова О.А., Курмуков И.А., Вольф Л.Я. Обзор практических рекомендаций ESPEN-2021 для онкологических больных. Часть 1. Клиническое питание и метаболизм 2022;3(3):140–52. DOI: 10.17816/clinutr111900</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Baumgartner A., Bargetzi A., Zueger N. et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation – a systematic review. Bone Marrow Transplant. 2017;52(4):506–13. DOI: 10.1038/bmt.2016.310</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Volchenkov S.A., Filatova L.V., Zyuzgin I.S. et al. The role of nutritional support on the recovery of patients with Hodgkin’s lymphoma during high-dose chemotherapy with autologous stem cell transplantation. Voprosy onkologii = Problems in Oncology 2023;69(4):722– 31. (In Russ.). DOI: 10.37469/0507-3758-2023-69-4-722-731</mixed-citation><mixed-citation xml:lang="ru">Волченков С.А., Филатова Л.В., Зюзгин И.С. и др. Влияние энтерального питания на восстановление пациентов с лимфомой Ходжкина во время проведения аутологичной трансплантации гемопоэтических стволовых клеток крови. Вопросы онкологии 2023;69(4):722–31. DOI: 10.37469/0507-3758-2023-69-4-722-731</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Saglam B., Albayrak M., Yıldız A. et al. The prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B-cell lymphoma. Hematol Transfus Cell Ther 2020;42(Suppl 1):21. DOI: 10.1016/j.htct.2020.09.040</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lee J.H., Oh S.Y., Lee H.S. et al. Pretreatment nutritional status and cardiovascular risk factors affect survival of diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2017;130(Suppl 1):2856. DOI: 10.1182/blood.V130.Suppl_1.2856.2856</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>He J., Yin H., Xia Y. et al. Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B-cell lymphoma. Leukemia Res 2021;110:106664. DOI: 10.1016/j.leukres.2021.106664</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Djurasinovic V.T., Jelicic J., Bila J. et al. Nutritional status of lymphoma patients – does it matter? Ann Oncol 2014; 25(Suppl. 4):iv535. DOI: 10.1093/annonc/mdu356.58</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mancuso S., Mattana M., Santoro M. et al. Host-related factors and cancer: malnutrition and non-Hodgkin lymphoma. Hematol Oncol 2022;40(3):320–31. DOI: 10.1002/hon.3002</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Ivanchey O.S. Nutritional status of patients with lymphoma and the possibility of its nutritional correction. Dis. … candidate of medical sciences. Novosibirsk, 2011. 23 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Иванчей О.С. Нутритивный статус больных лимфомами и возможности его пищевой коррекции. Дис. … канд. мед. наук. Новосибирск, 2011. 23 с.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Obukhova O.A., Kashiya Sh.R., Kurmukov I.A. et al. The use of additional oral nutrition during antitumor chemotherapy. Prospective randomized controlled trial. Vestnik intensivnoy terapii = Bulletin of Intensive Care 2009;(3):47–52. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Обухова О.А., Кашия Ш.Р., Курмуков И.А. и др. Применение дополнительного орального питания при проведении противоопухолевой химиотерапии. Проспективное рандомизированное контролируемое исследование. Вестник интенсивной терапии 2009;(3):47–52.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Oken M.M., Creech R.H., Tormey D.C. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649–55.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Cederholm T., Jensen G.L., Correia M.I.T.D. et al. GLIM criteria for the diagnosis of malnutrition – a consensus report from the global clinical nutrition community. Clin Nutr 2019;38(1):1–9. DOI: 10.1016/j.clnu.2018.08.002</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Obukhova O.A., Kurmukov I.A., Ryk A.A. The influence of nutritional support on nutritional status, quality of life and survival in cancer patients receiving systemic drug antitumor treatment. Klinicheskoe pitanie i metabolizm = Clinical Nutrition and Metabolism 2022;3(1):50–61. (In Russ.). DOI: 10.17816/clinutr104771</mixed-citation><mixed-citation xml:lang="ru">Обухова О.А., Курмуков И.А., Рык А.А. Влияние нутритивной поддержки на питательный статус, качество жизни и выживаемость у онкологических больных, получающих системное лекарственное противоопухолевое лечение. Клиническое питание и метаболизм 2022;3(1):50–61. DOI: 10.17816/clinutr104771</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Parenteral and enteral nutrition: national guidelines. Eds.: S.S. Petrikov, M.Sh. Khubutia, T.S. Popova. 2nd edn., revised and additional. Moscow: GEOTAR-Media, 2023. 1168 p. DOI: 10.33029/9704-7277-4-PAR-2023-1-1168</mixed-citation><mixed-citation xml:lang="ru">Парентеральное и энтеральное питание: национальное руководство. Под ред.: С.С. Петрикова, М.Ш. Хубутия, Т.С. Поповой. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2023. 1168 с. DOI: 10.33029/9704-7277-4-PAR-2023-1-1168</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Dietetics. Ed.: A.Yu. Baranovsky. 5th edn. Saint Petersburg: Peter, 2017. 1104 p.</mixed-citation><mixed-citation xml:lang="ru">Диетология. Под ред. А.Ю. Барановского. 5-е изд. СПб.: Питер, 2017. 1104 с.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Szeja N., Grosicki S. Nutritional status of patients with lymphoproliferative neoplasms before and after the first-line treatment. Expert Rev Hematol 2022;15(1):83–91. DOI: 10.1080/17474086.2022.2035717</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Yilmaz M., Atilla F.D., Sahin F., Saydam G. The effect of malnutrition on mortality in hospitalized patients with hematologic malignancy. Support Care Cancer 2020;28(3):1441–8. DOI: 10.1007/s00520-019-04952-5</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Park S., Han B., Cho J.W. et al. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer 2014;66(2):225–33. DOI: 10.1080/01635581.2014.867065.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Hébuterne X., Lemarié E., Michallet M. et al. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J Parenter Enteral Nutr 2014;38(2):196–204. DOI: 10.1177/0148607113502674</mixed-citation></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Ivanova A.S., Obukhova O.A., Kurmukov I.A., Volf L.Ya. Review of ESPEN-2021 Practice guidelines for patients with cancer. Part 2: interventions relevant to specific patient categories. Klinicheskoe pitanie i metabolizm = Clinical Nutrition and Metabolism 2022;3(4):193–206. (In Russ.). DOI: 10.17816/clinutr119059</mixed-citation><mixed-citation xml:lang="ru">Иванова А.С., Обухова О.А., Курмуков И.А., Вольф Л.Я. Обзор практических рекомендаций ESPEN-2021 для онкологических больных. Часть 2: частные вопросы нутритивной поддержки. Клиническое питание и метаболизм 2022;3(4):193–206. DOI: 10.17816/clinutr119059</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><mixed-citation>Agustsson T., Rydén M., Hoffstedt J. et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007;67(11):5531–7. DOI: 10.1158/0008-5472.CAN-06-4585</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Bourdel-Marchasson I., Blanc-Bisson C., Doussau A. et al. Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial. PLoS One 2014;9(9):e108687. DOI: 10.1371/journal.pone.0108687</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Epstein J.B., Barasch A. Taste disorders in cancer patients: pathogenesis, and approach to assessment and management. Oral Oncol 2010;46(2):77–81. DOI: 10.1016/j.oraloncology.2009.11.008</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ponticelli E., Clari M., Frigerio S. et al. Dysgeusia and healthrelated quality of life of cancer patients receiving chemotherapy: a cross-sectional study. Eur J Cancer Care 2017;26(2):e12633. DOI: 10.1111/ecc.12633</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ferreira M.H., Bezinelli L.M., de Paula Eduardo F. et al. Association of oral toxicity and taste changes during hematopoietic stem cell transplantation: a preliminary study. Support Care Cancer 2020;28(3):1277–87. DOI: 10.1007/s00520-019-04922-x</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Epstein J.B., de Andrade E., Silva S.M. et al. Taste disorders following cancer treatment: report of a case series. Support Care Cancer 2019;27(12):4587–95. DOI: 10.1007/s00520-019-04758-5</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Hinkelmann J.V., de Oliveira Possa L., de Oliveira C.A. et al. Food preferences and aversions of patients undergoing chemotherapy, radiotherapy and/or hematopoietic stem cell transplantation. Clinical Nutrition ESPEN 2021;44:331–6. DOI: 10.1016/j.clnesp.2021.05.023</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Van Lieshout R., Lize N., Tick L.W. et al. Nutrition-related problems, nutritional support practices and barriers to adherence to nutritional guidelines during intensive treatment for acute myeloid leukemia: patients’ and hematology nurses’ perspectives and experiences. Clin Nutr ESPEN 2021;48:446–55. DOI: 10.1016/j.clnesp.2021.12.029</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Prado C.M., Purcell S.A., Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle 2020;11(2):366–80. DOI: 10.1002/jcsm.12525</mixed-citation></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Volf L.Ya., Obukhova O.A., Egofarov N.M. et al. The impact of perioperative high-protein oral nutrition supplements on postoperative outcomes in primary lung cancer: the protocol of Russian prospective, randomised, multicenter study. Klinicheskoe pitanie i metabolizm = Clinical Nutrition and Metabolism 2023;4(1):5–18. (In Russ.). DOI: https://doi.org/10.17816/clinutr139225</mixed-citation><mixed-citation xml:lang="ru">Вольф Л.Я., Обухова О.А., Егофаров Н.М. и др. Влияние периоперационной высокобелковой нутритивной поддержки на послеоперационные результаты лечения больных первичным раком легкого: проект российского проспективного многоцентрового сравнительного исследования. Клиническое питание и метаболизм 2023;4(1):5–18. DOI: 10.17816/clinutr139225</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Obukhova O.A., Kurmukov I.A., Egofarov N.M. et al. Impact of perioperative high-protein nutritional support on postoperative outcomes in the treatment of primary lung cancer: Russian prospective multicenter comparative study (NUTRILUNC-study). Klinicheskoe pitanie i metabolizm = Clinical Nutrition and Metabolism 2023;4(3):150–64. (In Russ.). DOI: 10.17816/clinutr625481</mixed-citation><mixed-citation xml:lang="ru">Обухова О.А., Курмуков И.А., Егофаров Н.М. и др. Влияние периоперационной высокобелковой нутритивной поддержки на послеоперационные результаты лечения больных первичным раком легкого: российское проспективное многоцентровое сравнительное исследование (исследование NUTRILUNC). Клиническое питание и метаболизм 2023;4(3):150–64. DOI: 10.17816/clinutr625481</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Cvetković Z., Vučić V., Cvetković B. et al. Distribution of plasma fatty acids is associated with response to chemotherapy in nonHodgkin’s lymphoma patients. Med Oncol 2013;30(4):741. DOI: 10.1007/s12032-013-0741-2</mixed-citation><mixed-citation xml:lang="ru">Cvetković Z., Vučić V., Cvetković B. et al. Distribution of plasma fatty acids is associated with response to chemotherapy in non-Hodgkin’s lymphoma patients. Med Oncol 2013;30(4):741. DOI: 10.1007/s12032-013-0741-2</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><mixed-citation>Chagas T.R., Borges D.S., de Oliveira P.F. et al. Oral fish oil positively influences nutritional-inflammatory risk in patients with haematological malignancies during chemotherapy with an impact on long-term survival: a randomised clinical trial. J Hum Nutr Diet 2017;30(6):681–92. DOI: 10.1111/jhn.12471</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>McGlory C., Calder P.C., Nunes E.A. The influence of omega-3 fatty acids on skeletal muscle protein turnover in health, lisuse, and disease. Front Nutr 2019;6:144. DOI: 10.3389/fnut.2019.00144</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Barbosa-Cortés L., Martínez-Vieyra X., Mejía-Aranguré J.M. et al. Pilot study on the effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on body composition in children with acute lymphoblastic leukemia: randomized clinical trial. Clin Nutr 2023;42(9):1759–69. DOI: 10.1016/j.clnu.2023.06.022</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Amrousy D.El., El-Afify D., Khedr R., Ibrahim A.M. Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2022;69(7):e29496. DOI: 10.1002/pbc.29496</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Elbarbary N.S., Ismail E.A., Farahat R.K., El-Hamamsy M. Omega-3 fatty acids as an adjuvant therapy ameliorates methotrexate-induced hepatotoxicity in children and adolescents with acute lymphoblastic leukemia: a randomized placebocontrolled study. Nutrition. 2016;32(1):41–7. DOI: 10.1016/j.nut.2015.06.010</mixed-citation></ref></ref-list></back></article>
